{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:57:09Z","timestamp":1787727429965,"version":"build-2784847793"},"reference-count":4,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The oral acceptance of oclacitinib maleate (Apoquel\u00ae) chewable tablets administered twice daily for 7\u2009days at the labeled dose range of 0.4\u20130.6\u2009mg\/kg was evaluated in 121 dogs treated at ten general practice veterinary clinics in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Dogs that were enrolled in the study were client-owned, ranged from 1 to 14\u2009years of age, weighed 3.7 to 60.7\u2009kg, and required twice daily treatment with Apoquel for allergic or atopic dermatitis for 7\u2009days. One hundred and twenty-one (121) dogs with 1673 total dose administrations successfully completed the study and were included in the data summary. Out of a total number of 1673 administrations, 1533 (91.6%) were accepted voluntarily within 5\u2009min, 134 (8%) were consumed with assistance (with food treats or by pilling) outside of the 5\u2009min offering time and 6 (0.4%) doses were not consumed. The per dose percent acceptance rate for the 14 offered doses showed minimal variation ranging from 89.9 to 93.3%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Client-owned dogs from the general veterinary patient population that required treatment with oclacitinib found the chewable tablets to be very palatable and no aversion occurred with repeated dosing. Oclacitinib chewable tablets were well tolerated and are a palatable alternative to the film-coated tablet.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12917-022-03210-x","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T02:03:51Z","timestamp":1647482631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Acceptance of oclacitinib maleate (Apoquel\u00ae) chewable tablets in client-owned dogs with allergic and atopic dermatitis"],"prefix":"10.1186","volume":"18","author":[{"given":"Marike","family":"Visser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vickie","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Sture","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Caneva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"issue":"08","key":"3210_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.4236\/ojvm.2018.88011","volume":"08","author":"M Aleo","year":"2018","unstructured":"Aleo M, Ross S, Becskei C, Coscarelli E, King V, Darling M, et al. Palatability testing of Oral Chewables in veterinary medicine for dogs. Open J Vet Med. 2018;08(08):107\u201318.","journal-title":"Open J Vet Med"},{"key":"3210_CR2","unstructured":"Guideline on the demonstration of palatability of veterinary medicinal products, Regulation (EU) 2019\/6 (2021)."},{"issue":"4","key":"3210_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","volume":"37","author":"AJ Gonzales","year":"2014","unstructured":"Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib ( APOQUEL \u00ae ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317\u201324.","journal-title":"J Vet Pharmacol Ther"},{"issue":"10","key":"3210_CR4","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/archfami.9.10.1169","volume":"9","author":"JH Larosa","year":"2000","unstructured":"Larosa JH. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med. 2000;9(10):1169\u201375.","journal-title":"Arch Fam Med"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-022-03210-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-022-03210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T02:04:11Z","timestamp":1647482651000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-022-03210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":4,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1186\/s12917-022-03210-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1174474\/v1","asserted-by":"object"}]},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Zoetis Ethical Review Board and executed accordingly. Informed Owner Consent was obtained prior to any study activities occurring and adherence to best practice of veterinary care was documented in the medical records in compliance with relevant regulations and guidelines. The study is reported in accordance with ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employed by Zoetis Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}